http://jnci.oxfordjournals.org/cgi/reprint/djq246


Cohen J, Dibner MS, Wilson A. Development of and access to products for neglected diseases. *PLoS ONE* 2010 May;5(5) [RS 3014]  
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010610

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Getz K. FIPNet: pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials* 2009 Nov;Suppl:10-12,14,16 [RS 3012]  


Kaitin KI, editor. Rising protocol complexity, execution burden varies widely by phase and TA. *Tufts Center for the Study of Drug Development Impact Report* 2010 May/Jun;12(3) [RS 3010]  
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Getz KA. Sizing up the clinical research market. *Applied Clinical Trials* 2010 Mar;19(3):32-4 [RS 3009]  

Getz KA. With clinical data, less is more. *Applied Clinical Trials* 2010 Jan;19(1) [RS 3008]  
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

*Not available from the Center. Please contact a library or the publisher.*

Kaitin KI, editor. Rising demand is expanding scope and workload of regulatory affairs function. *Tufts Center for the Study of Drug Development Impact Report* 2010 Mar/Apr;12(2) [RS 3005]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Kaitin KI. Deconstructing the drug development process: the new face of innovation. *Clinical Pharmacology and Therapeutics* 2010 Mar;87(3):356-61 [RS 3004]


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*Not available from the Center. Please contact a library or the publisher.*


Milne C-P Kaitin KI. Translational medicine: an engine of change for bringing new technology to community health. 2009 Nov 4;1(5):1-4 [RS 2926]

http://stm.sciencemag.org/content/1/5/5cm5.full.pdf?sid=8b6b7e69-0ece-47d8-a333-2e1679b6cb25


Kaitin KI, editor. Drug approvals for neglected diseases increased along with more R&D funding. *Tufts Center for the Study of Drug Development Impact Report* 2009 Nov/Dec;11(6) [RS 2924]

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Getz KA. Into the aftermath of M&A. *Applied Clinical Trials* 2009 Sep;18(9) [RS 2921-A]

Kaitin KI, editor. Market exclusivity for first-in-class drugs has shortened to 2.5 years. *Tufts Center for the Study of Drug Development Impact Report* 2009 Sep/Oct;11(5) [RS 2921]

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


Getz KA. Are academia and NIH bastions of integrity? *Applied Clinical Trials* 2009 Jul;18(7) [RS 2913-A]
*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

*For sale at our website http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. Therapeutic peptides in clinical study in 2000—07 nearly doubled 1990s rate. Tufts Center for the Study of Drug Development Impact Report 2009 May/Jun;11(3) [RS 2910]
*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

*For sale at our website http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. Tufts Center for the Study of Drug Development Impact Report 2009 Mar/Apr;11(2) [RS 2905] *For sale at our website http://csdd.tufts.edu/reports/purchase_reports


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia* 2008; Issue 9:55-6 [RS 2833]

[http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm](http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm)


Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics* 2008 Nov;30(11):2133-45 [RS 2831]


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Kaitin KI, editor. Fast track designations more than doubled during the last five years. *Tufts Center for the Study of Drug Development Impact Report* 2008 Sep/Oct;10(5) [RS 2827]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Kaitin KI, editor. Postmarketing studies are becoming the norm in U.S., Europe, and Japan. *Tufts Center for the Study of Drug Development Impact Report* 2008 Jul-Aug;10(4) [RS 2823]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

[http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing](http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Getz K. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update* 2008 Apr;4:5-6 [RS 2815]

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*

Getz K. The heavy burden of protocol design. *Applied Clinical Trials* 2008 May;17(1) [RS 2811]  

Getz K. Tracking racial disparities in research. *Applied Clinical Trials* 2008 Jan;17(1) [RS 2810]  

Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials* 2008 Mar;17(3) [RS 2809]  

Kaitin KI, editor. Number of mAbs entering clinical study nearly tripled in last decade. *Tufts Center for the Study of Drug Development Impact Report* 2008 Mar/Apr:10(2) [RS 2807]
*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Kaitin KI. Obstacles and opportunities in new drug development. *Clinical Pharmacology & Therapeutics* 2008 Feb;83(2):210-2
[http://www.nature.com/clpt/journal/v83/n2/pdf/6100462a.pdf](http://www.nature.com/clpt/journal/v83/n2/pdf/6100462a.pdf) [RS 2802]

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Getz KA. In search of informed consent improvement. *Applied Clinical Trials* 2007 Nov;16(11):42,44-5 [RS 2729]

DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics* 2007;82(5):488-90 [RS 2728]
[http://www.nature.com/clpt/journal/v82/n5/full/6100393a.html](http://www.nature.com/clpt/journal/v82/n5/full/6100393a.html)
Cohen J. CEA is not a price control (letter). *Health Affairs* 2007;26(5):1505 [RS 2727]
http://content.healthaffairs.org/cgi/reprint/26/5/1505


Getz KA. Global clinical trials activity in the details. *Applied Clinical Trials* 2007 Sep;16(9):42-4 [RS 2723]


Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report* 2007 Sep/Oct;9(5) [RS 2721]
*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

http://www.springerlink.com/content/f03333rv1823w611/fulltext.pdf


Getz KA. CRA: jack of all trades. *Applied Clinical Trials* 2007 July;16(7):36,8 [RS 2717]
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials* 2007 May;16(5):35-6,8 [RS 2714]


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Getz KA. Industry trials poised to win back academia. *Applied Clinical Trials* 2007 Apr;16(4):40-2,4 [RS 2711]


Getz KA, Sergeant E, Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials* 2007 Apr;16(4):35-6,8 [RS 2710]


Getz K, Wenger J. High times for the CRO heavyweights. *Scrip supplements* 2007 Mar;5-6 [RS 2708]


Kaitin KI, editor. Pediatric study costs increased 8-fold since 2000 as complexity level grew. *Tufts Center for the Study of Drug Development Impact Report 2007* Mar/Apr;9(2) [RS 2707]

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)
*For sale at our website http://csdd.tufts.edu/reports/purchase_reports


Getz KA. Drowning in the sea of regulatory compliance. Applied Clinical Trials 2007 Feb;16(2):32, 34 [RS 2704]
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

*For sale at our website http://csdd.tufts.edu/reports/purchase_reports

Getz KA. Hitching a ride with the speed demons of drug development. Applied Clinical Trials 2006 Dec;15(12):22,24 [RS 2626]
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454


Cohen J Cairns C Paquette C Faden L. Comparing patient access to pharmaceuticals in the UK and US. Applied Health Economics and Health Policy 2006;5(3):177-87 [RS 2624]


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875
Kaitin KI, editor. Cost to develop new biotech products is estimated to average $1.2 billion. *Tufts Center for the Study of Drug Development Impact Report 2006 Nov/Dec;8(6) [RS 2621]*

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


Getz KA. Spotting the 'new' managed site networks. *Applied Clinical Trials 2006 Sep;15(9):34,36 [RS 2619]*

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


Kaitin KI, editor. Number of vaccines entering clinical study rose only modestly since 1990s. *Tufts Center for the Study of Drug Development Impact Report 2006 Jul/Aug;8(4) [RS 2616]*

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568


http://content.healthaffairs.org/cgi/eletters/25/2/461


*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports

*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports

Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials* 2006 Apr;15(4):42, 44 [RS 2606]
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473

*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report* 2006 Jan/Feb;8(1) [RS 2603]
*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports

Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials* 2006 Jan;15(1):38, 40 [RS 2601]  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials* 2005 Sep;14(9):34-6 [RS 2517]  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&pageID=1

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials* 2005 Aug;14(8):56 [RS 2515]  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279


Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report* 2005 Nov/Dec;7(6) [RS 2510]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Reichert JM  Rosensweig CJ  Faden LB  Dewitz MC. Monoclonal antibody successes in the clinic. *Nature Biotechnology* 2005 Sep;23(9):1073-8 [RS 2509]
Also available at

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI, editor. Protein therapeutic success rates increase with biotech advance. *Tufts Center for the Study of Drug Development Impact Report* 2005 Mar/Apr;7(2) [RS 2502]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

Kaitin KI, editor. Decline in drug approvals is driving industry, FDA to enhance efficiency. *Tufts Center for the Study of Drug Development Impact Report* 2005 Jan/Feb;7(1) [RS 2501]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing)* 2004 Winter:12-17  [RS 2423]


Cohen J. The emergence of a *de facto* fourth hurdle in the US. *Regulatory Affairs Journal -- Pharma* 2004 Dec;15(12):867-70 [RS 2419]

Kaitin KI, editor. Incremental R&D creates safer, more effective drugs & fosters competition. *Tufts Center for the Study of Drug Development Impact Report* 2004 Nov/Dec;6(6) [RS 2418]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


[http://www.nature.com/nbt/journal/v22/n12/pdf/nbt1204-1513.pdf](http://www.nature.com/nbt/journal/v22/n12/pdf/nbt1204-1513.pdf)

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI, editor. FDA requested postmarketing studies in 73% of recent new drug approvals. *Tufts Center for the Study of Drug Development Impact Report* 2004 Jul/Aug;6(4) [RS 2408]

*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. Therapeutic class a critical determinant of drug development time & cost. *Tufts Center for the Study of Drug Development Impact Report* 2004 May/Jun;6(3) [RS 2405]

*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. Faster review, longer response time mark new EU biopharmaceuticals. *Tufts Center for the Study of Drug Development Impact Report* 2004 Mar/Apr;6(2) [RS 2403]

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*


Kaitin KI, editor. FDA’s fast track initiative cut total drug development time by 3 years. *Tufts Center for the Study of Drug Development Impact Report* 2003 Nov/Dec;5(6) [RS 2314]

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)*

Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report* 2003 Sep/Oct;5(5) [RS 2312]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


[http://www.nature.com/nrd/journal/v2/n9/pdf/nrd1178.pdf](http://www.nature.com/nrd/journal/v2/n9/pdf/nrd1178.pdf)

Kaitin KI, editor. CROs provide gateway to worldwide clinical trial recruitment efforts. *Tufts Center for the Study of Drug Development Impact Report* 2003 Jul/Aug;5(4) [RS 2308]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)

*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report* 2003 Jan/Feb;5(1) [RS 2301]
*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. Tufts Center for the Study of Drug Development Impact Report 2002 Nov/Dec;4(6) [RS 2218] *For sale at our website http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. Approval times for priority-reviewed new drugs declined under PDUFA. *Tufts Center for the Study of Drug Development Impact Report* 2002 Jul/Aug;4(4) [RS 2213]

*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


[http://www.nature.com/nbt/journal/v20/n7/pdf/nbt0702-659.pdf](http://www.nature.com/nbt/journal/v20/n7/pdf/nbt0702-659.pdf)

Cohen J Chee J. Pharmaceutical benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes* 2002;10(4):221-7 [RS 2211]


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI. From the Editor-in-Chief: regulatory reform at the crossroads. *Drug Information Journal* 2002;36(2):245-6 [RS 2204]


22
Reichert JM. Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics* 2002;4(2):110-8 [RS 2203]


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona) 2001 18 Mar [RS 2123]

*Not available from the Center. Please contact a library or the publisher.*

Kaitin KI, participant. The importance of innovation in pharmaceutical research. *Pfizer Journal* 2001;4(5) [RS 2122]


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


*For sale at our website* [http://csdd.tufts.edu/reports/purchase_reports](http://csdd.tufts.edu/reports/purchase_reports)


Kaitin KI, editor. Pharmaceutical firms making quicker decisions on compounds in R&D. *Tufts Center for the Study of Drug Development Impact Report* 2001 May/Jun;3(3) [RS 2110]
*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. Tufts Center survey describes disease management practice in the U.S. *Tufts Center for the Study of Drug Development Impact Report* 2001 Mar/Apr;3(2) [RS 2106]
*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report* 2001 Jan/Feb;3(1) [RS 2102]

*For sale at our website* http://csdd.tufts.edu/reports/purchase_reports


http://www.diahome.org/content/abstract/2000/dij1556.pdf

Kaitin KI, editor. Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report* 2000 Dec;2(9) [RS 2023]


Kaitin KI. Don’t turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial* 2000 Sep;2(7) [RS 2018]


http://www.acnp.org/g4/GN401000182/Default.htm


Kaitin KI, editor. Planning, independence, feedback keep global R&D projects on track. *Tufts Center for the Study of Drug Development Impact Report* 1999 Sep;1(3) [RS 9912]  


Lasagna L. Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. *Journal of Clinical Pharmacology* 1998;38:570-1, 575-6 [RS 9810]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.


*Not available from the Center. Please contact a library or the publisher.


Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. Drug Information Journal 1997;31(1):27-33 [RS 9715]

Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. Medical Marketing & Media 1996 Dec;31(12):88-9 [RS 9714]

http://www.nature.com/clpt/journal/v60/n6/pdf/clpt1996527a.pdf

DiMasi JA. *Written testimony*. House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996 [RS 9625]


Kaitin KI. *Statement*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session: 81-7, 100-1 [RS 9623]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


Shulman SR Seibring M Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate*. Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8 [RS 9506]


*Not available from the Center. Please contact a library or the publisher.*


Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider. For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995 [PS 9596]


*Not available from the Center. Please contact a library or the publisher.*


Kaitin KI Bryant NR Lasagna L. The role of the research-based pharmaceutical industry in medical progress in the United States. Journal of Clinical Pharmacology 1993;33(5):412-7 [RS 9377]


Shulman SR Raiford DS. Promotional elements in educational programs: FDA attempts to wipe the slate clean. P&T 1992;17:661-73 [RS 9274]
*Not available from the Center. Please contact a library or the publisher.*

Kaitin KI Walsh HL. Are initiatives to speed the new drug approval process working? Drug Information Journal 1992;26:341-9 [RS 9271]


DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. *Journal of Clinical Research and Pharmacoepidemiology* 1991;5:19-33 [RS 9158]


*Not available from the Center. Please contact a library or the publisher.*


Lasagna L. Le attivitá del Centro per lo Studio dello Sviluppo dei Farmaci. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26 [RS 9053]


Shulman SR Raiford DS. FDA regulations provide broader access to unapproved drugs. *Journal of Clinical Pharmacology* 1990;30:585-7 [RS 9048]


Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary* 1988 Jan;23:79 [RS 8830]

DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology* 1988;41(9):939-41 [RS 8829]


*Not available from the Center. Please contact a library or the publisher.*


Kaitin KI.  Impact of generic drugs on the pharmaceutical marketplace.  *Private Practice* 1986 Sep;18:18-20 (Originally appeared as "Generic firms shun research, share rewards.") [RS 8705]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*

Weintraub M Northington F. Drugs that wouldn't die. *Journal of the American Medical Association* 1986 May 2;255(17):2327-8 [RS 8699]


*Not available from the Center. Please contact a library or the publisher.*


Spivey RN Lasagna L Trimble AG. New drug applications: how long to gain approval? *Clinical Pharmacology and Therapeutics* 1985 Apr;37(4):361-6 [RS 8585]


*Not available from the Center. Please contact a library or the publisher.*


Wardell WM. Is pharmaceutical innovation declining? *Pharmaceutical Technology* 1982 Sep [RS 8262]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.


Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982 [RS 8250]

*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*

Hansen RW.  *Effects of incremental costs on pharmaceutical innovation.*  (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980 [RS 8059]

Hansen RW.  *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies.*  (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980 [RS 8058]

Wardell WM.  Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources.  In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association, 1980:139-50 [RS 8057]

*Not available from the Center. Please contact a library or the publisher.*

Wardell WM.  Drug therapy (a response to questions on specific aspects of drug regulation).  *Private Practice* 1980 Oct:24-31 [RS 8056]

*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


Lasagna L.  Pharmacology's labs have moved faster than the regulators.  *Medical Tribune* 1980 May 7;21:17 [RS 8051]

*Not available from the Center. Please contact a library or the publisher.


*Not available from the Center. Please contact a library or the publisher.


*Not available from the Center. Please contact a library or the publisher.


*Not available from the Center. Please contact a library or the publisher.


*Not available from the Center. Please contact a library or the publisher.

*Not available from the Center. Please contact a library or the publisher.*


Merrill RA. *Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials.* Rochester NY: Center for the Study of Drug Development, Apr 1980 [PS 8032]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology* 1979;43(1):27-33 [RS 7939]

Lasagna L. Prescription drugs: the investment with the biggest dividends. *Private Practice* 1979 May;11(5):42-3 [RS 7938]


*N*ot available from the Center. Please contact a library or the publisher.


*N*ot available from the Center. Please contact a library or the publisher.


*N*ot available from the Center. Please contact a library or the publisher.


Lasagna L. The diseases and drug needs of the Third World. *Journal of Chronic Diseases* 1979;32(6):413-4 [RS 7926-A]

53


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


Landau RL. *What you should know about estrogens, or the perils of Pauline.* Rochester NY: Center for the Study of Drug Development, Jun 1978 [PS 7816]


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


*Not available from the Center. Please contact a library or the publisher.*


